However, treatment with the PKM2 targeting compound TEPP-46 and PD-1 checkpoint blockade significantly increased the populations of GzmB+ and NKp46+ NK cells and decreased tumor cell survival compared with the TGF-β1-treated group (Fig. 6c–g). The gene discussed is TGFB1; the disease is neoplasm.